The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Atrial fibrillation management: we can do better

Atrial fibrillation management: we can do better

Publication date: Friday, 02 August 2019
Contributor(s): Dr John Robson

Atrial fibrillation (AF) management has been transformed within the last decade by revised clinical guidance and availability of new drugs. Aspirin monotherapy, once accounting for almost half of all antithrombotic prescriptions for AF, is now an obsolete therapy. Anticoagulation is the treatment of choice for AF and direct oral anticoagulants (DOACs) have overtaken warfarin as the drug of first choice for new starters. However, management of one in four people with AF remains suboptimal, and this article reviews the major issues around antithrombotic and other treatments for AF.
Sponsorship information:
This publication has been produced in collaboration with PHE & NHS England who contributed towards the content. BHF & Stroke Association have contributed towards the publication funding but had no role in the design or content. Final editorial control rests with the authors and editors.
Topics covered:
Category: Editorial
Edition: Volume 11 Number 1 February 2019
Print edition page(s): S29
Contributor(s): Dr John Robson

Article search and filter